MK-6240
Sponsors
Abbvie Deutschland GmbH & Co. KG, Biogen Idec Research Limited, Washington University School Of Medicine, University of Southern California, Columbia University
Conditions
Alzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer's disease (AD)DementiaDominantly Inherited Alzheimer Disease (DIAD)Mild Cognitive ImpairmentMild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disease Dementia
Phase 1
Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
WithdrawnCTIS2022-501644-15-00
Target: 327Updated: 2023-02-20
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease
CompletedCTIS2022-500691-59-00
End: 2024-06-27Target: 98Updated: 2024-06-03
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD)
Active, not recruitingCTIS2024-515198-91-00
Start: 2022-12-20Target: 24Updated: 2025-07-04